VALNEVA SE (AYJ.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:AYJ - FR0004056851 - Common Stock
3.872 EUR
+0.08 (+2.16%)
AYJ gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. AYJ may be in some trouble as it scores bad on both profitability and health. AYJ is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AYJ has reported negative net income.
AYJ had a negative operating cash flow in the past year.
In the past 5 years AYJ always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: AYJ reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of AYJ (-18.09%) is comparable to the rest of the industry.
AYJ has a Return On Equity (-45.87%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.09% | ||
| ROE | -45.87% | ||
| ROIC | N/A |
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AYJ's Gross Margin of 48.94% is in line compared to the rest of the industry. AYJ outperforms 44.58% of its industry peers.
AYJ's Gross Margin has declined in the last couple of years.
AYJ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
2. Health
2.1 Basic Checks
AYJ does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AYJ has been increased compared to 1 year ago.
AYJ has more shares outstanding than it did 5 years ago.
AYJ has a better debt/assets ratio than last year.
2.2 Solvency
AYJ has an Altman-Z score of -0.26. This is a bad value and indicates that AYJ is not financially healthy and even has some risk of bankruptcy.
AYJ's Altman-Z score of -0.26 is in line compared to the rest of the industry. AYJ outperforms 49.40% of its industry peers.
AYJ has a Debt/Equity ratio of 0.80. This is a neutral value indicating AYJ is somewhat dependend on debt financing.
AYJ has a Debt to Equity ratio (0.80) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.26 |
ROIC/WACCN/A
WACC7.51%
2.3 Liquidity
A Current Ratio of 2.27 indicates that AYJ has no problem at all paying its short term obligations.
AYJ has a Current ratio of 2.27. This is comparable to the rest of the industry: AYJ outperforms 49.40% of its industry peers.
AYJ has a Quick Ratio of 1.77. This is a normal value and indicates that AYJ is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.77, AYJ perfoms like the industry average, outperforming 44.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.77 |
3. Growth
3.1 Past
AYJ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1180.00%.
AYJ shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.32%.
Measured over the past years, AYJ shows a small growth in Revenue. The Revenue has been growing by 6.09% on average per year.
EPS 1Y (TTM)-1180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-271.43%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%-35.76%
3.2 Future
The Earnings Per Share is expected to grow by 55.46% on average over the next years. This is a very strong growth
Based on estimates for the next years, AYJ will show a quite strong growth in Revenue. The Revenue will grow by 17.32% on average per year.
EPS Next Y-639.98%
EPS Next 2Y-113.91%
EPS Next 3Y108.86%
EPS Next 5Y55.46%
Revenue Next Year-5.39%
Revenue Next 2Y3.18%
Revenue Next 3Y28.09%
Revenue Next 5Y17.32%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AYJ. In the last year negative earnings were reported.
Also next year AYJ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as AYJ's earnings are expected to grow with 108.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-113.91%
EPS Next 3Y108.86%
5. Dividend
5.1 Amount
AYJ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:AYJ (12/8/2025, 7:00:00 PM)
3.872
+0.08 (+2.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners22.69%
Inst Owner ChangeN/A
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap332.67M
Revenue(TTM)169.58M
Net Income(TTM)-85.51M
Analysts81.82
Price Target7.19 (85.69%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.78%
Min EPS beat(2)56.68%
Max EPS beat(2)62.87%
EPS beat(4)3
Avg EPS beat(4)14.13%
Min EPS beat(4)-115.24%
Max EPS beat(4)62.87%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)-23.48%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)21.69%
Min Revenue beat(2)16.4%
Max Revenue beat(2)26.97%
Revenue beat(4)3
Avg Revenue beat(4)10.09%
Min Revenue beat(4)-4.78%
Max Revenue beat(4)26.97%
Revenue beat(8)4
Avg Revenue beat(8)1.3%
Revenue beat(12)7
Avg Revenue beat(12)19.63%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.07%
PT rev (3m)-1.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10%
EPS NY rev (1m)-2.87%
EPS NY rev (3m)-4.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.54%
Revenue NY rev (1m)-1.66%
Revenue NY rev (3m)-9.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.14 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.78 | ||
| P/tB | 2.05 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS3.39
BVpS2.17
TBVpS1.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.09% | ||
| ROE | -45.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.94% | ||
| FCFM | N/A |
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 71.71% | ||
| Cap/Sales | 5.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.77 | ||
| Altman-Z | -0.26 |
F-Score4
WACC7.51%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-271.43%
EPS Next Y-639.98%
EPS Next 2Y-113.91%
EPS Next 3Y108.86%
EPS Next 5Y55.46%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%-35.76%
Revenue Next Year-5.39%
Revenue Next 2Y3.18%
Revenue Next 3Y28.09%
Revenue Next 5Y17.32%
EBIT growth 1Y-49.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-294.29%
EBIT Next 3Y47.89%
EBIT Next 5Y30.38%
FCF growth 1Y88.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.27%
OCF growth 3YN/A
OCF growth 5YN/A
VALNEVA SE / AYJ.DE FAQ
What is the fundamental rating for AYJ stock?
ChartMill assigns a fundamental rating of 2 / 10 to AYJ.DE.
What is the valuation status for AYJ stock?
ChartMill assigns a valuation rating of 1 / 10 to VALNEVA SE (AYJ.DE). This can be considered as Overvalued.
How profitable is VALNEVA SE (AYJ.DE) stock?
VALNEVA SE (AYJ.DE) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for AYJ stock?
The Earnings per Share (EPS) of VALNEVA SE (AYJ.DE) is expected to decline by -639.98% in the next year.